PMID: 9441329Jan 24, 1998Paper

Gemcitabine: a new chemotherapy agent for solid cancers

Revue médicale de Bruxelles
J Klastersky, A Awada

Abstract

Gemcitabine, a new nucleotide analogue, is a promising chemotherapeutic agent for pancreatic, lung, ovarian and breast carcinomas. Its low toxicity (mainly hematologic) makes it a good choice for palliative treatment in patients who would otherwise be unable to tolerate aggressive therapy. The combination of gemcitabine with other anticancer agents such as cisplatin and anthracyclines appears to be associated with high response rates. Finally, gemcitabine is a potent radiosensitizing agent and should definitely be tested in combination with radiotherapy mainly in locally advanced disease.

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Related Papers

Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
Ralf WilkowskiEckhart Dühmke
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
O Caffo
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Jin-hong ParkEun Kyung Choi
© 2021 Meta ULC. All rights reserved